Outcome of Preserved Mitral Valve Apparatus During Mitral Valve Replacement (EarlyOutcome)
Outcome of Preservation of Mitral Valve Leaflets During Mitral Replacement
Are there differences in outcome of mitral valve replacement with preservation of mitral apparatus among rheumatic and/or ischemic mitral lesions?.
Mitral valve replacement with preservation of leaflets, and added coronary artery-bypass surgery, when indicated, is it a feasible and reproducible procedure?.
The study was designed to compare outcome after prosthetic mitral replacement with preservation of mitral apparatus for rheumatic valve disease with outcome of replacement for ischemic myocardium and mitral valve disease, The outcomes will be guided by clinical assessment. and echo-cardiograph.
Обзор исследования
Статус
Условия
Подробное описание
Objectives: The aim is to compare outcome of modified preservation of mitral valve apparatus during prosthetic mitral replacement for rheumatic versus myocardial ischemia &mitral valve disease.
Methods ;This prospective cross-sectional comparative study will include 50 patients with isolated rheumatic mitral valve disease (group A) and 50 patients with mitral disease and myocardial ischemia (group B), surgery is expected to be performed between 2017 and 2020 at one center. All patients will have modified preservation of mitral apparatus during prosthetic mitral replacement. Additionally, group B patients will have bypass grafts to left anterior descending and/or posterior descending / right coronary artery. Data will be collected and analyzed.
The Institutional Review Board (IRB), Ethics Committee (EC)-approval and consent of each patient were obtained.
Criteria for inclusion of patients and exclusion of others were determined according to the guide lines.
Statistical analysis::
Qualitative variables and their association among both groups were studied by applying Chi-square test and Fisher Exact test. Quantitative variables among both groups were compared by applying independent samples t-test. P < 0.05 values mean statistically-significant results.
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
-
Ismailia, Египет, +064
- Suez Canal University
-
Ismailia, Египет, 002-064
- Suez Canal University
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria::
Mitral stenosis (MS)
- symptoms are severely limiting and cannot be managed with diuresis and heart rate control.
Mitral regurgitation(MR):
* acute severe MR require surgical correction for hemo-dynamics and relief of symptoms .
Chronic primary mitral regurgitation:
* rheumatic heart disease: replacement before irreversible changes occur can be curative.
Mixed Mitral Stenosis and Mitral Regurgitation:
- If beta blockers and diuretics do not relieve symptoms, replacement should be performed only in patients who have severe limiting symptoms.
- Myocardial ischemia associating or complicated with miral valve disease.
Exclusion criteria
- Patients showing good response to medical therapy, and Cases complicated by:
- ineffective endocarditis,
- previous myocardial re-vascularization
- ischemic ventricular septal defect,
- left ventricular aneurysm,
- Ruptured papillary muscles of mitral apparatus.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Фальшивый компаратор: Group A
50 patients with isolated rheumatic mitral valve disease (group A)
|
St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
Другие имена:
|
|
Другой: Group B
50 patients with mitral disease and myocardial ischemia (group B)
|
St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Smoking index
Временное ограничение: One week before surgery(or during first clinical visit) .
|
Number of Packs every day X number of years of smoking= Pack.year,
|
One week before surgery(or during first clinical visit) .
|
|
Age and gender for each participant
Временное ограничение: One week before surgery .
|
Males above 40 years and Females above 45 years need pre-operative coronary angio-graph
|
One week before surgery .
|
|
For each participant: pathological:type of mitral valve lesion
Временное ограничение: Seven days before surgery .
|
severe stenosis with mitral area < 1 cm square, severe regurgitation, or mixed lesions
|
Seven days before surgery .
|
|
For each participant: etiological :type of mitral valve lesion
Временное ограничение: Seven days before surgery .
|
Rheumatic: distorted thickened leaflets,thickened fibrosed chordae
|
Seven days before surgery .
|
|
For each participant: etiological :type of mitral valve lesion
Временное ограничение: Seven days before surgery- echo-cardiograph.
|
Rheumatic: distorted thickened leaflets,thickened fibrosed chordae or ischemic incompetence
|
Seven days before surgery- echo-cardiograph.
|
|
For each participant:, assessing sub-valvular apparatus
Временное ограничение: One week before surgery. with Echo-cardiograph.
|
Thickened chordae, ruptured chordae, ischemia of papillary muscles or lateral ventricular wall.
|
One week before surgery. with Echo-cardiograph.
|
|
Abascal echo-cardiographic mitral valve score (Wilkins score)
Временное ограничение: One week before surgery.with Echo-cardiograph
|
:if score is 8 or less it is good for balloon valvo-plasty, if > 8 surgery is recommended ( leaflet mobility, thickness and calcification.
Fourthly, sub-valvular thickening., higher scores = more deterioration
|
One week before surgery.with Echo-cardiograph
|
|
left ventricular wall motion abnormality
Временное ограничение: one week before surgery - with an echo-cardiograph
|
hypokinesia, Akinesia, Dyskinesia of certain segment(s)
|
one week before surgery - with an echo-cardiograph
|
|
Number of participants with Signs of left ventricular dysfunction
Временное ограничение: seven days before surgery echo-cardiograph examination
|
low ejection fraction <52%, low stroke volume< 70 ml, low cardiac output <5 litres per minute
|
seven days before surgery echo-cardiograph examination
|
|
Number of participants with pre-operative coronary artery disease
Временное ограничение: seven days before surgery, coronary angio-graph
|
Expected on clinical bases and .proved
by Echo-cardiograph-findings
|
seven days before surgery, coronary angio-graph
|
|
Number of participants with pre-operative ischemic complications
Временное ограничение: seven days before surgery echo-cardiograph examination
|
left ventricular thrombi, septal and left ventricular wall thickness in mm .
|
seven days before surgery echo-cardiograph examination
|
|
Assessment of any evolving new prosthetic valve dysfunction
Временное ограничение: intra-operative trans-esophageal echo-cardiograph examination
|
Left atrioventricular outflow stenosis, prosthetic dysfunction due to preservation of valve apparatus
|
intra-operative trans-esophageal echo-cardiograph examination
|
|
Change in post-operative left ventricular functions
Временное ограничение: 5 days post-operatively and end of 6th and 12 months after surgery with Echo-Cardiograph
|
: Low Fractional Shortening < 28% , Ejection fraction < 40%,, increased left ventricular dimensions and volume
|
5 days post-operatively and end of 6th and 12 months after surgery with Echo-Cardiograph
|
|
Change of Prosthetic mitral valve functions
Временное ограничение: Monthly through study completion up to 12 months after surgery..... with Echo-cardiograph
|
Development of para-valvular leak or central jet of regurgitation or stuck valve by a thrombus
|
Monthly through study completion up to 12 months after surgery..... with Echo-cardiograph
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
changes on Clinical examination
Временное ограничение: Monthly up to 12 months after surgery)
|
local and general Examination,: a new murmur, evolving heart failure
|
Monthly up to 12 months after surgery)
|
|
Changes in Results of Prothrombin time, concentration and.International normalized ratio
Временное ограничение: .Monthly through study completion up to 12 months.
|
Adjust dose of oral anticoagulant.( between double and half to three times the control) Dose usually ranges between 1 and 11 mg warfarin tablet daily.
|
.Monthly through study completion up to 12 months.
|
|
Mortality and Morbidity
Временное ограничение: Monthly through study completion up to 12 months.
|
cause of mortality, type of morbidity: wound infection, hypertrophied scar, Kiloid Formation
|
Monthly through study completion up to 12 months.
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Директор по исследованиям: Mohamed A. allaban, PhD, Suez Canal University, FOM- Research Ethics Committee
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 2796#
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Сроки обмена IPD
Критерии совместного доступа к IPD
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- МКФ
- КСО
Информация о лекарствах и устройствах, исследовательские документы
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .